Home › NDC Lookup › RxCUI directory › RxCUI 1545780

Lomustine 40 MG Oral Capsule [Gleostine] — RxCUI 1545780

RxNorm drug concept · Semantic branded drug
RxCUI 1545780 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1545780
Official nameLomustine 40 MG Oral Capsule [Gleostine]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asGleostine 40 MG Oral Capsule
FDA products mapped6
Package NDCs mapped6
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lomustine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's a chemotherapy capsule used for brain tumors, both ones that start in the brain and ones that spread there, usually after surgery or radiation. It's also used with other chemo...
  • You take one single dose by mouth, and then you do not repeat it for at least 6 weeks. Your dose may be several capsules of different colors. Never take extra, since too much can b...
  • Nausea, vomiting, mouth sores, and hair loss are common. The most important effect is a drop in blood counts that shows up about 4 to 6 weeks after a dose, so you'll have regular b...
  • Call right away for fever or signs of infection, unusual bleeding or bruising, new cough or shortness of breath, vision changes, or confusion. These can be signs of serious effects...
📖 Read our full Lomustine guide →

🕸️ Concept Web — How Lomustine 40 MG Oral Capsule [Gleostine] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lomustine 40 MG Oral Capsule [Gleostine] RxCUI 1545780

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lomustine 6466
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gleostine 1545771
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lomustine Oral Capsule 372631
    • Lomustine Oral Product 1165319
    • Lomustine Pill 1165320
    • Lomustine Oral Capsule [Gleostine] 1545773
    • Gleostine Oral Product 1545774
    • Gleostine Pill 1545775
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lomustine 40 MG Oral Capsule SCD · 197896
  • Lomustine 40 MG SCDC · 316162
  • Lomustine Oral Capsule SCDF · 372631
  • Lomustine Oral Product SCDG · 1165319
  • Lomustine Pill SCDG · 1165320

Brand-Name Concepts

  • Lomustine 40 MG [Gleostine] SBDC · 1545779
  • Lomustine Oral Capsule [Gleostine] SBDF · 1545773
  • Gleostine Oral Product SBDG · 1545774
  • Gleostine Pill SBDG · 1545775
  • Gleostine BN · 1545771

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 1545780 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0340-05 1 BOTTLE in 1 CARTON (24338-340-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
24338-0341-05 1 BOTTLE in 1 CARTON (24338-341-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
24338-0342-05 1 BOTTLE in 1 CARTON (24338-342-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
58181-3040-05 1 BOTTLE in 1 CARTON (58181-3040-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
58181-3041-05 1 BOTTLE in 1 CARTON (58181-3041-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
58181-3042-05 1 BOTTLE in 1 CARTON (58181-3042-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
Observed labelers: Azurity Pharmaceuticals, Inc. (3) · NextSource Biotechnology, LLC (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.